Migraine Briefs

CGRP monoclonal antibodies safe and effective for episodic migraine


 

Key clinical point: Calcitonin gene-related peptide-binding monoclonal antibody (CGRP mAb) is an effective and safe preventive treatment for episodic migraine.

Major finding: CGRP mAb therapy was associated with a significant reduction in monthly migraine days (weighted mean difference [WMD], −1.44; P less than .00001) and acute migraine-specific medication days (WMD, −1.28; P less than .00001), with an improvement in 50% responder rate (RR, 1.51; 95% CI,  1.37-1.66) compared with placebo. Adverse events and treatment withdrawal rates did not differ between groups.

Study details: Meta-analysis of 11 randomized controlled trials including 4,402 patients.

Disclosures: This study was supported by the National Natural Science Foundation of China and the Wuhan science and technology plan project. The authors declared no conflicts of interest.

Citation: Deng H et al. BMC Neurol. 2020 Feb 15. doi: 10.1186/s12883-020-01633-3 .

Next Article: